Status: Recruiting
Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis
The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).
Participants needed: 280
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Aresus Pharma GmbHUpdated: Aug 22, 2025Locations: 1
Eligibility criteria
Patients willing to participate, obtained written informed consent. [+5]
TA is within 5 cm of an incompletely healed wound or infected area of the skin. [+24]